Status: Recruiting
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)
Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Tessera Therapeutics, Inc.Updated: May 18, 2026Locations: 3
Eligibility criteria
Males or females who are 18 to 70 years of age, inclusive, at the time of signin... [+13]
Presence of genetic variation in SERPINA1 gene that may disrupt the function of... [+12]